Taurine für Insomnie
B Evidenz Mindestens eine randomisierte Studie unterstützt dies, mit überwiegend konsistenten Ergebnissen.Based on 11 studies (1 meta-analysis) with 32 total participants. Results are mixed across studies.
Fazit
Based on 11 studies (1 meta-analysis) with 32 total participants. Results are mixed across studies.
Key Study Findings
Population: Patients with atopic dermatitis and mild-moderate negative emotions
Population: Insomnia patients
Population: Insomnia patients
Population: Adolescents
Population: None
Key Statistics
11
Studien
32
Teilnehmer
Mixed
Bewertung
Referenced Papers
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Übliche Dosierungen
- sleep:
- 500-2,000 mg, 1 hour before bed
Obergrenze: 3,000 mg/day considered safe in clinical studies
In der Forschung untersuchte Dosierungen
| Dosierung | Dauer | Wirkung | N |
|---|---|---|---|
| Lactobacillus reuteri E9 (dose not specified) | -- | Positive | -- |
| None | 12 weeks | Positive | 32 |
| None | -- | Neutral | -- |
| None | -- | Neutral | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
Beste Einnahmezeit: 1 hour before bed
Safety & Side Effects
Gemeldete Nebenwirkungen
- ⚠ Generally well tolerated
- ⚠ Mild GI discomfort at high doses
- ⚠ Drowsiness (desired for sleep use)
Bekannte Wechselwirkungen
- ● Lithium — taurine may alter lithium excretion
- ● Antihypertensives — may have additive blood pressure lowering effects
- ● CNS depressants — potential additive sedative effects
Tolerierbare Höchstaufnahmemenge: 3,000 mg/day considered safe in clinical studies
Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.
Frequently Asked Questions
Does Taurine help with Insomnie?
How much Taurine should I take for Insomnie?
Are there side effects of Taurine?
How strong is the evidence for Taurine and Insomnie?
Related Evidence
Andere Inhaltsstoffe für Insomnie
Taurine für andere Beschwerden
References
- [1] Liuyan Zhu et al.. Biomedicines. 2026. Serum Amino Acid and Fatty Acid Metabolites as Predictors of Sleep Disorders in Children: A Risk Prediction Model. doi:10.3390/biomedicines14030546 PubMed
- [2] Wanying Zhai et al.. Asian Pac J Allergy Immunol. 2025. Efficacy and associated neurotransmitters of digital cognitive behavior therapy for atopic dermatitis: A comparative effectiveness research. doi:10.12932/AP-100223-1542 PubMed
- [3] Yongcheng Jiang et al.. Front Biosci (Landmark Ed). 2025. Lactobacillus reuteri E9 Regulates Sleep Disorders Through Its Metabolite GABA. doi:10.31083/FBL39587 PubMed
- [4] Williams Kobik et al.. PLoS One. 2024. Energy drinks in Tamale: Understanding youth perceptions, consumption patterns, and related factors. doi:10.1371/journal.pone.0289391 PubMed
- [5] Cyriac Abby Philips. Front Med (Lausanne). 2024. Commonly encountered symptoms and their management in patients with cirrhosis. doi:10.3389/fmed.2024.1442525 PubMed
- [6] Paola Silva Maldonado et al.. Rev Esp Salud Publica. 2022. [Energy drink consumption patterns and its adverse effects on adolescent health.]. PubMed
- [7] Yu-Han Yang et al.. Zhongguo Zhong Yao Za Zhi. 2020. [Establishment of rat heart-kidney insomnia model consistent with traditional Chinese medicine syndrome and its serum metabolomics]. doi:10.19540/j.cnki.cjcmm.20190524.502 PubMed
- [8] Kirk J Brower. Alcohol. 2015. Assessment and treatment of insomnia in adult patients with alcohol use disorders. doi:10.1016/j.alcohol.2014.12.003 PubMed
- [9] Nicola J Kalk et al.. Br J Clin Pharmacol. 2014. The clinical pharmacology of acamprosate. doi:10.1111/bcp.12070 PubMed
- [10] Bhanu Prakash Kolla et al.. Alcohol Alcohol. 2011. Pharmacological treatment of insomnia in alcohol recovery: a systematic review. doi:10.1093/alcalc/agr073 PubMed
- [11] Kevin A Clauson et al.. J Am Pharm Assoc (2003). 2008. Safety issues associated with commercially available energy drinks. doi:10.1331/JAPhA.2008.07055 PubMed
- [12] Atsushi Takeda et al.. Nutr Neurosci. 2008. Suppressive effect of Yokukansan on excessive release of glutamate and aspartate in the hippocampus of zinc-deficient rats. doi:10.1179/147683008X301414 PubMed
FDA-Haftungsausschluss: Diese Aussagen wurden nicht von der Food and Drug Administration bewertet. Die Produkte und Informationen auf dieser Website sind nicht dazu bestimmt, Krankheiten zu diagnostizieren, zu behandeln, zu heilen oder zu verhindern. Die dargestellten Evidenzbewertungen basieren auf unserer Analyse veröffentlichter begutachteter Forschung und stellen keine medizinische Beratung dar. Konsultieren Sie immer Ihren Arzt, bevor Sie mit der Einnahme von Nahrungsergänzungsmitteln beginnen.